Showing stories 1 - 10 of about 89
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) focuses on commercializing cancer ...
Related articles »
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA): Thursday's trading session saw Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) rising 5.48% and closed at $19.44. It opened at a price of $18.16 which touched an intraday high of $20.00, before moving down to close ...
Ariad Pharmaceutical Receives Outperform Rating from RBC Capital (ARIA)
The Utah People's PostRelated articles »
Traders Recap: Zale Corporation , Multiband Corp, Saks Inc, Ariad ...
Zale Corporation (NYSE:ZLC) shares gained 25.74% to $6.79. The company on May 22 reported net income of $5.1 million, or 13 cents per share, compared with a loss of $4.5 million, or 14 cents per share, in the same quarter the year before.
ARIAD PHARMACEUTICALS, INC. : ARIAD to Present at the Deutsche Bank ...
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Deutsche Bank 38th Annual Healthcare Conference being held in Boston.
Related articles »
ARIAD PHARMACEUTICALS, INC. : ARIAD to Present at UBS Global Healthcare ...
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the UBS Global Healthcare Conference being held in New York City.
Related articles »
Biotech New Bundle: ZIOPHARM, MannKind, VIVUS, Ariad Pharmaceuticals ...
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded 5.48% higher to close last trading session at $19.44, extending rally after its presentation at the UBS Global Healthcare Conference.
The Wendy's Co (NASDAQ:WEN) falls by 5.56%, Ariad Pharmaceuticals, Inc ...
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA): The company shares dipped by 3.59% in Wednesday's trading session. The Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) opening share price was $17.51 which rose to an intraday price of $17.58 before falling to ...
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Infinity Pharmaceuticals, Inc ...
Wilmington, DE -- (SBWIRE) -- 05/16/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), and Oncothyreon Inc (NASDAQ:ONTY).
Related articles »
ARIAD PHARMACEUTICALS, INC. : ARIAD Reports First Quarter 2013 Financial ...
Ariad reports $6.4M in 1Q sales of leukemia pill Bioscience Technology
Related articles »
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter, including revenue from its first cancer medicine, Iclusig� (ponatinib), which was approved last December by the U.S.
Ariad Pharmaceutical (ARIA) Releases Quarterly Earnings Results
ZolmaxAriad reports $6.4M in 1Q sales of leukemia pill Bioscience Technology
Related articles »
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Ariad Pharmaceuticals Inc ...
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), PDL BioPharma, Inc. (NASDAQ:PDLI), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Added to Growing Stock Report's Biotech Gainers Watch List.
Related articles »
Health Sector Top Gainers, VIVUS, Inc, Escalon Medical Corp, ZIOPHARM ...
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is scheduled to present at the Deutsche Bank 38th Annual Healthcare Conference in Boston.
Related articles »